192 related articles for article (PubMed ID: 19417029)
21. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
[TBL] [Abstract][Full Text] [Related]
23. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
24. UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):50-5. PubMed ID: 11098494
[TBL] [Abstract][Full Text] [Related]
25. A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.
Gong J; Cho M; Gupta R; Synold TW; Frankel P; Ruel C; Fakih M; Chung V; Lim D; Chao J
Oncologist; 2019 Aug; 24(8):1137-1145. PubMed ID: 30710067
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
28. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
Schott AF; Rae JM; Griffith KA; Hayes DF; Sterns V; Baker LH
Cancer Chemother Pharmacol; 2006 Jul; 58(1):129-35. PubMed ID: 16283312
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer.
Kosmas C; Agelaki S; Giannakakis T; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V
Oncology; 2002; 62(2):103-9. PubMed ID: 11914594
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
31. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
[TBL] [Abstract][Full Text] [Related]
32. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.
Vogel C; O'Rourke M; Winer E; Hochster H; Chang A; Adamkiewicz B; White R; McGuirt C
Ann Oncol; 1999 Apr; 10(4):397-402. PubMed ID: 10370781
[TBL] [Abstract][Full Text] [Related]
33. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
[TBL] [Abstract][Full Text] [Related]
34. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study.
Baweja M; Suman VJ; Fitch TR; Mailliard JA; Bernath A; Rowland KM; Alberts SR; Kaur JS; Perez EA;
Ann Oncol; 2006 Apr; 17(4):623-9. PubMed ID: 16520332
[TBL] [Abstract][Full Text] [Related]
38. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
40. The effects of food on the pharmacokinetic profile of oral vinorelbine.
Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
